| Name | CYP2A6 |
|---|---|
| Synonyms | CPA 6; CPA6; Flavoprotein linked monooxygenase; CYP2A; P450C2A; P450PB; CYP2A3; CYP2A6… |
| Name | nicotine |
|---|---|
| CAS |
| PubMed | Abstract | RScore(About this table) | |
|---|---|---|---|
| 19169923 | Ray R, Tyndale RF, Lerman C: Nicotine dependence pharmacogenetics: role of genetic variation in nicotine-metabolizing enzymes. J Neurogenet. 2009;23(3):252-61. Epub 2009 Jan 23. Inhibition of the CYP2A6 enzyme to slow nicotine metabolism is a promising approach to increase nicotine availability and potentially reduce harm from tobacco smoking. |
145(1,3,3,5) | Details |
| 19702528 | Di YM, Chow VD, Yang LP, Zhou SF: Structure, Function, Regulation and Polymorphism of Human Cytochrome P450 2A6. Curr Drug Metab. 2009 Sep 1. Because CYP2A6 is responsible for 70-80% of the initial metabolism of nicotine, CYP2A6 has been proposed to be a novel target for smoking cessation. |
123(1,2,2,13) | Details |
| 19279561 | Ho MK, Mwenifumbo JC, Al Koudsi N, Okuyemi KS, Ahluwalia JS, Benowitz NL, Tyndale RF: Association of nicotine metabolite ratio and CYP2A6 genotype with smoking cessation treatment in African-American light smokers. Clin Pharmacol Ther. 2009 Jun;85(6):635-43. Epub 2009 Mar 11. |
114(1,2,2,4) | Details |
| 19018727 | Rossini A, de Almeida Simao T, Albano RM, Pinto LF: CYP2A6 polymorphisms and risk for tobacco-related cancers. Pharmacogenomics. 2008 Nov;9(11):1737-52. The psychoactive compound responsible for tobacco addiction, nicotine and the potent carcinogens present at high concentrations either in cigarette mainstream smoke or in smokeless tobacco products, 4-(methylnitrosamino)-1-(3-pyridyl)- (NNK) and N-nitrosonornicotine (NNN) can be metabolized by CYP2A6. |
88(1,1,1,8) | Details |
| 20136358 | Mwenifumbo JC, Zhou Q, Benowitz NL, Sellers EM, Tyndale RF: New CYP2A6 gene deletion and conversion variants in a population of Black African descent. Pharmacogenomics. 2010 Feb;11(2):189-98. AIMS: Cytochrome P450 2A6 (CYP2A6) is a human enzyme best known for metabolizing nicotine and nitrosamine precarcinogens. |
88(1,1,1,8) | Details |
| 20233178 | Hukkanen J, Jacob Iii P, Peng M, Dempsey D, Benowitz NL: Effects of nicotine on cytochrome P450 2A6 and 2E1 activities. Br J Clin Pharmacol. 2010 Feb;69(2):152-9. AIMS: Smoking slows the metabolism of nicotine and accelerates the metabolism of chlorzoxazone, which are probe reactions for cytochrome P450 2A6 (CYP2A6) and CYP2E1 activities, respectively. |
88(1,1,2,3) | Details |
| 19365400 | Al Koudsi N, Ahluwalia JS, Lin SK, Sellers EM, Tyndale RF: A novel CYP2A6 allele (CYP2A6*35) resulting in an amino-acid substitution (Asn438Tyr) is associated with lower CYP2A6 activity in vivo. Pharmacogenomics J. 2009 Aug;9(4):274-82. Epub 2009 Apr 14. We determined their haplotype, allele frequencies, effect on CYP2A6 activity in vivo, as well as their stability and ability to metabolize nicotine in vitro. |
87(1,1,1,7) | Details |
| 20012030 | Al Koudsi N, Hoffmann EB, Assadzadeh A, Tyndale RF: Hepatic CYP2A6 levels and nicotine metabolism: impact of genetic, physiological, environmental, and epigenetic factors. Eur J Clin Pharmacol. 2010 Mar;66(3):239-51. Epub 2009 Dec 9. RESULTS: Liver samples with variant CYP2A6 alleles had significantly lower CYP2A6 protein expression, nicotine C-oxidation activity, and affinity for nicotine. |
86(1,1,1,6) | Details |
| 20307138 | Al Koudsi N, Tyndale RF: Hepatic CYP2B6 is altered by genetic, physiologic, and environmental factors but plays little role in nicotine metabolism. Xenobiotica. 2010 Mar 22. A weak correlation between CYP2B6 and nicotine C-oxidation activity was observed, which was abrogated when controlling for CYP2A6 protein levels. |
81(1,1,1,1) | Details |
| 19090569 | Van Damme S, Bultinck P: Conceptual DFT properties-based 3D QSAR: analysis of inhibitors of the nicotine metabolizing CYP2A6 enzyme. J Comput Chem. 2009 Sep;30(12):1749-57. |
81(1,1,1,1) | Details |
| 19029401 | Derby KS, Cuthrell K, Caberto C, Carmella SG, Franke AA, Hecht SS, Murphy SE, Le Marchand L: Nicotine metabolism in three ethnic/racial groups with different risks of lung cancer. Cancer Epidemiol Biomarkers Prev. 2008 Dec;17(12):3526-35. Epub 2008 Nov 24. We assessed CYP2A6 activity by nicotine metabolite ratio (total /total and metabolite ratio (1,7-dimethyl / in 12 h urine. |
70(0,2,3,5) | Details |
| 19959692 | Ho MK, Faseru B, Choi WS, Nollen NL, Mayo MS, Thomas JL, Okuyemi KS, Ahluwalia JS, Benowitz NL, Tyndale RF: Utility and relationships of biomarkers of smoking in African-American light smokers. Cancer Epidemiol Biomarkers Prev. 2009 Dec;18(12):3426-34. Further, variability in CYP2A6, the enzyme that mediates formation of COT from nicotine and its metabolism to (3HC), may limit the usefulness of COT. |
33(0,1,1,3) | Details |
| 19184652 | Mwenifumbo JC, Tyndale RF: Molecular genetics of nicotine metabolism. . Handb Exp Pharmacol. 2009;(192):235-59. Genetic studies have demonstrated that polymorphisms in CYP2A6, the primary enzyme responsible for nicotine breakdown, make a sizable contribution to the wide range of nicotine metabolic capacity observed in humans. |
32(0,1,1,2) | Details |
| 19434638 | Chougnet A, Woggon WD, Locher E, Schilling B: Synthesis and in vitro activity of heterocyclic inhibitors of CYP2A6 and CYP2A13, two cytochrome P450 enzymes present in the respiratory tract. Chembiochem. 2009 Jun 15;10(9):1562-7. These compounds were tested as inhibitors of CYP2A6 and CYP2A13--two cytochrome P450 enzymes present in the respiratory tract--with a view to preventing the formation of carcinogenic metabolites of nicotine and inhibiting the metabolism of fragrances. 1-Substituted imidazoles bearing short alkyl chains displayed IC (50) values of around 2 microM for both enzymes, together with high vapour pressures. |
32(0,1,1,2) | Details |
| 19251795 | Quaak M, van Schayck CP, Knaapen AM, van Schooten FJ: Genetic variation as a predictor of smoking cessation success. Eur Respir J. 2009 Mar;33(3):468-80. Recently, it has been shown that genetic variants in the dopaminergic system, opioid receptors, the -metabolising enzyme CYP2B6 and the nicotine-metabolising enzyme CYP2A6 may play an important role in predicting smoking cessation responses to nicotine replacement therapy and treatment. |
31(0,1,1,1) | Details |
| 19184645 | Benowitz NL, Hukkanen J, Jacob P 3rd: Nicotine chemistry, metabolism, kinetics and biomarkers. Handb Exp Pharmacol. 2009;(192):29-60. Nicotine is metabolized primarily by the liver enzymes CYP2A6, UDPglucuronosyltransferase (UGT), and flavin-containing monooxygenase (FMO). |
31(0,1,1,1) | Details |
| 19019380 | Petsalo A, Turpeinen M, Pelkonen O, Tolonen A: Analysis of nine drugs and their cytochrome P450-specific probe metabolites from urine by liquid chromatography-tandem mass spectrometry utilizing sub 2 microm particle size column. J Chromatogr A. 2008 Dec 26;1215(1-2):107-15. Epub 2008 Nov 7. CYP-specific metabolites of (CYP1A2), nicotine (CYP2A6), (CYP2B6), repaglinide (CYP2C8), losartan (CYP2C9), (CYP2C19 and CYP3A4), dextromethorphan (CYP2D6), chlorzoxazone (CYP2E1) and midazolam (CYP3A4) were all analyzed using the same LC/MS/MS method with a single analytical run, either after a one-at-a-time dose or cocktail-type dosing of the parent drugs. |
31(0,1,1,1) | Details |
| 19300303 | Swan GE, Lessov-Schlaggar CN, Bergen AW, He Y, Tyndale RF, Benowitz NL: Genetic and environmental influences on the ratio of 3'hydroxycotinine to in plasma and urine. Pharmacogenet Genomics. 2009 May;19(5):388-98. DNA was genotyped to confirm zygosity and for variation in the gene for the primary nicotine metabolic enzyme, CYP2A6 (variants genotyped: *1B, *1 x 2, *2, *4, *9, *12). |
9(0,0,1,4) | Details |
| 19251817 | DeVore NM, Smith BD, Wang JL, Lushington GH, Scott EE: Key residues controlling binding of diverse ligands to human cytochrome P450 2A enzymes. Drug Metab Dispos. 2009 Jun;37(6):1319-27. Epub 2009 Feb 27. Although the human lung cytochrome P450 2A13 (CYP2A13) and its liver counterpart cytochrome P450 2A6 (CYP2A6) are 94% identical in amino acid sequence, they metabolize a number of substrates with substantially different efficiencies. To determine differences in binding for a diverse set of cytochrome P450 2A ligands, we have measured the spectral binding affinities (K (D)) for nicotine, phenethyl isothiocyanate (PEITC), 2'-methoxyacetophenone (MAP), and 8-methoxypsoralen. |
5(0,0,0,5) | Details |
| 19415821 | Tang X, Guo S, Sun H, Song X, Jiang Z, Sheng L, Zhou D, Hu Y, Chen D: Gene-gene interactions of CYP2A6 and MAOA polymorphisms on smoking behavior in Chinese male population. Pharmacogenet Genomics. 2009 May;19(5):345-52. OBJECTIVES: Nicotine is the major psychoactive ingredient in tobacco, and is responsible for dependence through the nicotine-stimulated reward pathway mediated by the central dopaminergic system. |
4(0,0,0,4) | Details |
| 19845430 | Murai K, Yamazaki H, Nakagawa K, Kawai R, Kamataki T: Deactivation of anti-cancer drug letrozole to a metabolite by polymorphic cytochrome P450 2A6 in human liver microsomes. Xenobiotica. 2009 Nov;39(11):795-802. |
4(0,0,0,4) | Details |
| 19923441 | Zhou X, Zhuo X, Xie F, Kluetzman K, Shu YZ, Humphreys WG, Ding X: Role of CYP2A5 in the clearance of nicotine and insights from studies on a Cyp2a5-null mouse model. J Pharmacol Exp Ther. 2010 Feb;332(2):578-87. Epub 2009 Nov 18. CYP2A5, a mouse cytochrome P450 monooxygenase that shows high similarities to human CYP2A6 and CYP2A13 in protein sequence and substrate specificity, is expressed in multiple tissues, including the liver, kidney, lung, and nasal mucosa. |
2(0,0,0,2) | Details |
| 19793020 | Iwahashi K, Aoki J: A review of smoking behavior and smokers evidence (chemical modification, inducing nicotine metabolism, and individual variations by genotype: dopaminergic function and personality traits). Drug Chem Toxicol. 2009;32(4):301-6. The nicotine metabolism of CYP2A6 (CYP2A6*1A,*1B, and *1C), and the cholecystokinin (CCK; which modulates the release of and CCK-A receptor gene and personality traits for NEO-FFI, was investigated for the mechanism for elucidation of the smoking behavior in Japanese populations. |
2(0,0,0,2) | Details |
| 20192103 | Ahijevych K: Biological models for studying and assessing tobacco use. Annu Rev Nurs Res. 2009;27:145-68. An overview of selected biomarkers of tobacco exposure in individuals includes exhaled (the proximate metabolite of nicotine), and measurement of an individual's puffing pattern termed smoking topography. Illustrative of this area are twin studies, nicotinic receptors, CYP2A6 polymorphisms, and genes that impact receptors. |
1(0,0,0,1) | Details |